IMBiologics

로고

About us
Platform Technology
- IMBolution Technology
- ePENDY Technology
Pipeline
- IMB-101
- IMB-102
- IMB-201
- IMB-202
- IMB-401/IMB-402
Media Room
- Notice
- News
- Gallery
Careers
- Culture
- Recruiting Information

언어선택 ENG

KOR ENG

전체메뉴

About us
Platform Technology
- IMBolution Technology
- ePENDY Technology
Pipeline
- IMB-101
- IMB-102
- IMB-201
- IMB-202
- IMB-401/IMB-402
Media Room
- Notice
- News
- Gallery
Careers
- Culture
- Recruiting Information

News

Innovative Medicines based on
ImmunoModulatory Biologics

Media Room
About us Platform Technology Pipeline Media Room Careers
News
Notice News Gallery

Total20

(January 19, 2021) IMBiologics raises 4B KRW seed round to accelerate R&D activities

For more information, please visit : IMBiologics News (full article available in Korean)

2022-03-07

(November 20, 2020) IMBiologics inks a worldwide exclusive licensing deal for anti-OX40L/TNF BsAb

For more information, please visit : IMBiologics News (full article available in Korean)

2022-03-07

1 2 3

Total

President(CEO) : Gyongsik Ha
260, Changnyong-daero, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea